Pulmonx Corporation (LUNG)
Pulmonx Statistics
Share Statistics
Pulmonx has 39.8M shares outstanding. The number of shares has increased by 2.47% in one year.
Shares Outstanding | 39.8M |
Shares Change (YoY) | 2.47% |
Shares Change (QoQ) | 0.86% |
Owned by Institutions (%) | 91.33% |
Shares Floating | 34.23M |
Failed to Deliver (FTD) Shares | 27 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.25M, so 3.18% of the outstanding shares have been sold short.
Short Interest | 1.25M |
Short % of Shares Out | 3.18% |
Short % of Float | 3.5% |
Short Ratio (days to cover) | 5.29 |
Valuation Ratios
The PE ratio is -4.71 and the forward PE ratio is -3.83. Pulmonx's PEG ratio is 0.47.
PE Ratio | -4.71 |
Forward PE | -3.83 |
PS Ratio | 3.17 |
Forward PS | 0.8 |
PB Ratio | 3.09 |
P/FCF Ratio | -8.05 |
PEG Ratio | 0.47 |
Enterprise Valuation
Pulmonx Corporation has an Enterprise Value (EV) of 441.82M.
EV / Earnings | -7.83 |
EV / Sales | 5.27 |
EV / EBITDA | -7.66 |
EV / EBIT | -7.66 |
EV / FCF | -13.39 |
Financial Position
The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.66.
Current Ratio | 5.58 |
Quick Ratio | 4.88 |
Debt / Equity | 0.66 |
Total Debt / Capitalization | 39.69 |
Cash Flow / Debt | -0.56 |
Interest Coverage | -16.45 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on capital (ROIC) is -40.92%.
Return on Equity (ROE) | -0.66% |
Return on Assets (ROA) | -0.35% |
Return on Capital (ROIC) | -40.92% |
Revenue Per Employee | $287,934.71 |
Profits Per Employee | $-193,793.81 |
Employee Count | 291 |
Asset Turnover | 0.51 |
Inventory Turnover | 1.29 |
Taxes
Income Tax | 500K |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -26.43% in the last 52 weeks. The beta is 0.51, so Pulmonx's price volatility has been higher than the market average.
Beta | 0.51 |
52-Week Price Change | -26.43% |
50-Day Moving Average | 7.16 |
200-Day Moving Average | 6.91 |
Relative Strength Index (RSI) | 40.97 |
Average Volume (20 Days) | 314.15K |
Income Statement
In the last 12 months, Pulmonx had revenue of 83.79M and earned -56.39M in profits. Earnings per share was -1.44.
Revenue | 83.79M |
Gross Profit | 62M |
Operating Income | -57.7M |
Net Income | -56.39M |
EBITDA | -57.7M |
EBIT | -57.7M |
Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has 70.91M in cash and 56.47M in debt, giving a net cash position of 14.43M.
Cash & Cash Equivalents | 70.91M |
Total Debt | 56.47M |
Net Cash | 14.43M |
Retained Earnings | -467.56M |
Total Assets | 162.85M |
Working Capital | 111.81M |
Cash Flow
In the last 12 months, operating cash flow was -31.54M and capital expenditures -1.45M, giving a free cash flow of -32.98M.
Operating Cash Flow | -31.54M |
Capital Expenditures | -1.45M |
Free Cash Flow | -32.98M |
FCF Per Share | -0.84 |
Margins
Gross margin is 74%, with operating and profit margins of -68.87% and -67.3%.
Gross Margin | 74% |
Operating Margin | -68.87% |
Pretax Margin | -66.71% |
Profit Margin | -67.3% |
EBITDA Margin | -68.87% |
EBIT Margin | -68.87% |
FCF Margin | -39.37% |
Dividends & Yields
LUNG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -21.11% |
FCF Yield | -12.16% |
Analyst Forecast
The average price target for LUNG is $12, which is 76% higher than the current price. The consensus rating is "Buy".
Price Target | $12 |
Price Target Difference | 76% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Scores
Altman Z-Score | -1.8 |
Piotroski F-Score | 4 |